Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Mark G. Foletta

At a glance: Mark G. Foletta is Director at Dexcom (DXCM). Their latest SEC Form 4, filed Aug 4, 2026, reported a sale of $160K. On file: 0 purchase lines ($0) and 6 sale lines ($742K).

Disclosed holdings: about $3.9M of DXCM stock: 48,852 shares (including shares held indirectly, e.g. through a trust or fund) reported on their latest Form 4 (filed Aug 4, 2026), valued at the Nov 19, 2026 close of $79.36. This counts only DXCM shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at Amn Healthcare Services Inc (AMN); Director at Dexcom Inc (DXCM)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $742K

Mark G. Foletta's InsiderPrint

7 trades from SEC Form 4 filings, 2024 to 2026, drawn as one fingerprint.

InsiderPrint of Mark G. Foletta: 7 trades, 2024 to 20262024: 1 buy, 0 sales2025: 0 buys, 0 sales2026: 0 buys, 6 sales

Reading this print: Mostly sells, trading about 3 times a year, typically $62K a trade; most sales are on a pre-planned 10b5-1 schedule; trades in the same month most years.

  • Bump outward: a purchase (1)
  • Dent inward: a sale (6)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Erika T. DavisSee Remarks · PFGC · 97% match
  2. Anthony FolgerDirector · CSPI · 96% match
  3. MPM Oncology Innovations Fund LP10% Owner · AKTS · 95% match
  4. Kevin TanCFO · SLDB · 95% match
  5. George R. NebleDirector · EVER · 95% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2024

From the SEC's insider data sets: each open-market buy by Mark G. Foletta, matched to how the stock did over the next 90 days against the S&P 500.

0 of 1 buy beat the S&P 500 (0%), median -15.5% vs. the index. Small sample: treat with care. All insider buys: 46%.

StockFiled90 days vs. S&P 500
AMNMar 7, 2024-15.5%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Aug 4SEC DXCMDexcom Inc Sell Plan 2,00050,852 held (−4%) $80.00 $160K -0.8%
Aug 4SEC DXCMDexcom Inc Sell Plan 2,00048,852 held (−4%) $85.32 $171K -7.0%
Jun 17SEC DXCMDexcom Inc Sell Plan 3,80153,051 held (−7%) $74.10 $282K +7.1%
Jun 17SEC DXCMDexcom Inc Sell Plan 19952,852 held (−0%) $74.82 $15K +6.1%
Jun 17SEC AMNAmn Healthcare Services Inc Sell Plan 1,68119,917 held (−8%) $31.07 $52K +13.7%
Jun 17SEC AMNAmn Healthcare Services Inc Sell Plan 2,00017,917 held (−10%) $31.07 $62K +13.7%
  • Sell

    Director Mark G Foletta sold $160K of DXCM at $80.00 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Mark G Foletta sold $171K of DXCM at $85.32 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Mark G Foletta sold $282K of DXCM at $74.10 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Mark G Foletta sold $15K of DXCM at $74.82 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Mark G Foletta sold $52K of AMN at $31.07 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Mark G Foletta sold $62K of AMN at $31.07 — pre-scheduled 10b5-1 plan sale.

Follow Mark G. Foletta

Get one email when Mark G. Foletta files a new purchase or sale. Free.

At most one email a day about Mark G. Foletta, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.